Abstract:Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antigen receptor-T cell therapies specific for two targets, and two distinct classes of bispecific T cell engagers, a vaccine, and an oncolytic virus have joined cytokines as a standard of cancer care. At the same time, scientific progress has delivered vast amounts of new knowledge. For example, advances in technologies such as single-cell sequencing and spatial transcriptomics have provided deep insights into the immunobiology of the tumor microenvironment. With this rapid clinical and scientific progress, the field of cancer immunotherapy is currently at a critical inflection point, with potential for exponential growth over the next decade. Recognizing this, the Society for Immunotherapy of Cancer convened a diverse group of experts in cancer immunotherapy representing academia, the pharmaceutical and biotechnology industries, patient advocacy, and the regulatory community to identify current opportunities and challenges with the goal of prioritizing areas with the highest potential for clinical impact. The consensus group identified seven high-priority areas of current opportunity for the field: mechanisms of antitumor activity and toxicity; mechanisms of drug resistance; biomarkers and biospecimens; unique aspects of novel therapeutics; host and environmental interactions; premalignant immunity, immune interception, and immunoprevention; and clinical trial design, endpoints, and conduct. Additionally, potential roadblocks to progress were discussed, and several topics were identified as cross-cutting tools for optimization, each with potential to impact multiple scientific priority areas. These cross-cutting tools include preclinical models, data curation and sharing, biopsies and biospecimens, diversification of funding sources, definitions and standards, and patient engagement. Finally, three key guiding principles were identified that will both optimize and maximize progress in the field. These include engaging the patient community; cultivating diversity, equity, inclusion, and accessibility; and leveraging the power of artificial intelligence to accelerate progress. Here, we present the outcomes of these discussions as a strategic vision to galvanize the field for the next decade of exponential progress in cancer immunotherapy.

A decade of immune-checkpoint inhibitors in cancer therapy

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

Cancer Immunotherapy: an Evolving Paradigm

Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology

Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors

A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

Tumor Immune Checkpoints and Their Associated Inhibitors

[Immune-checkpoints: the new anti-cancer immunotherapies]

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4

Immune Checkpoints in Cancers: From Signaling to the Clinic

The future of immune checkpoint therapy

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).

Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy

Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy